We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Laser Intervention in the Early Stages of AMD
Previous Study | Return to List | Next Study

Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04776031
Recruitment Status : Active, not recruiting
First Posted : March 1, 2021
Last Update Posted : May 23, 2022
Neuroscience Trials Australia
Information provided by (Responsible Party):
Lutronic Vision, Inc

Brief Summary:
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.

Condition or disease Intervention/treatment Phase
Early Age Related Macular Degeneration (Disorder) Device: R:GEN Laser System Not Applicable

Detailed Description:
This clinical study is a prospective, single-center, single-arm, open-label, pilot study to evaluate the safety and tolerability of the R:GEN Laser System and to collect information on the severity of AMD in subjects with bilateral large drusen. All participants will receive the intervention at the baseline visit and at the 24-week visit. All participants will be evaluated at 24 and 48 weeks from the baseline visit.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the R:GEN Laser System as an Intervention in Subjects With Early Stages of Age Related Macular Degeneration (AMD) for Safety and Exploratory Efficacy Outcomes
Actual Study Start Date : February 15, 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Laser Treatment
Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
Device: R:GEN Laser System
Laser Treatment

Primary Outcome Measures :
  1. To access the safety and tolerability of the R:GEN Laser System in subjects with the early stages of AMD. [ Time Frame: up to 48 weeks ]
    Incidences of Serious Adverse Events, Serious Adverse Device Effects, Unanticipated Serious Adverse Device Effects

Secondary Outcome Measures :
  1. To evaluate the progression in severity of AMD after treatment with the R:GEN Laser System at 24 weeks and 48 weeks post-treatment. [ Time Frame: 24 weeks and 48 weeks post-treatment ]
    Evidence of the presence of late AMD

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults 50 years and over
  • Best Corrected Visual Acuity [BCVA] of 6/12 [20/40] or better in each eye
  • Bilateral large drusen: at least 1 druse ≥125 µm in each eye within an inner macular zone [a circle with a radius of 1500 µm centered on the fovea], and with or without pigment;
  • Ability and willingness to consent, receive laser treatment, and complete all visits

Exclusion Criteria:

  • Any evidence of definite reticular pseudo drusen [RPD] > 2-disc areas [DAs] as seen either by fundus autofluorescence [FAF] or near-infrared reflectance [NIR] enface imaging in each eye
  • Any evidence of geographic atrophy [GA] within the macula [a circle with a radius of 3000 microns centered on the fovea] excluding peripapillary atrophy
  • Any evidence of nascent GA, or worse evidence of atrophy (complete RPE and outer retinal atrophy) as determined by OCT: including the subsidence of the inner nuclear layer and outer plexiform layer [OPL], or the presence of a hyporeflective wedge-shaped band within the limits of the OPL, and accompanied by attenuation or absence of the RPE and hypertransmission into the choroid
  • Current choroidal neovascularization [CNV], (determined on multimodal imaging [MMI], but angiogram not required) or past evidence of CNV, including the presence of non-exudative macular neovascularization [NE-MNV] [determined by OCT-A]
  • Asymptomatic sub-retinal fluid [SRF] [a slither < 50 µm allowed]
  • Any current ocular disease or condition in the study eye including diseases affecting the optic nerve, the anterior chamber, and autoimmune or systemic inflammatory conditions in which there are ocular manifestations that either are undergoing or require treatment, or history of ocular disease within 3 months of screening
  • A central macular serous pigment epithelial detachment greater than 1000 µm in diameter; a central macular drusenoid detachment > 1000 µm with hyper reflective foci [HRF] and hypertransmission; or any central macular drusenoid pigment epithelial detachments >2000 µm
  • Previous retinal or ocular surgery within 3 months prior to screening, the effects of which may now or in the future complicate assessment of AMD
  • Any history of prior laser treatment to the retina
  • Any systemic medication known to be toxic to the retina
  • Known hypersensitivity to fluorescein or indocyanine green
  • Sensitivity to application of a contact lens
  • History or presence of uncontrolled glaucoma, ocular hypertension, or intraocular pressure > 24 mmHg
  • Cataract which in the opinion of the investigator limits evaluation of the retina or requires cataract surgery within 12 months
  • Pregnant or lactating women
  • Subject who is currently in a clinical study, or has received other active investigational therapy, within 30 days of the screening visit
  • Subject who is considered ineligible for this study in the investigator's medical judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04776031

Layout table for location information
Australia, Victoria
Centre for Eye Research Australia - Royal Victorian Eye & Ear Hospital
East Melbourne, Victoria, Australia, 3002
Sponsors and Collaborators
Lutronic Vision, Inc
Neuroscience Trials Australia
Layout table for investigator information
Principal Investigator: Robyn H Guymer, MBBS, PhD Center for Eye Research Australia
Layout table for additonal information
Responsible Party: Lutronic Vision, Inc
ClinicalTrials.gov Identifier: NCT04776031    
Other Study ID Numbers: 56173
First Posted: March 1, 2021    Key Record Dates
Last Update Posted: May 23, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Lutronic Vision, Inc:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
High risk early age related macular degeneration
Laser Treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases